Aortic valve stenosis” is an often-overlooked condition and a growing health concern in ageing societies such as Thailand.

MiRus announced that it launched a U.S. multi-center early feasibility study for its Siegel transcatheter heart valve (THV).

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Over 100 patients successfully treated with the DurAVR ® THV, including de novo (first time) aortic stenosis cases, valve-in-valve (ViV) patients and complex anatomies such as bicuspid aortic valve ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve ...

GE HealthCare Technologies Inc. GEHC recently announced the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the ongoing American College of Cardiology (ACC) Annual Scientific Session & Expo.

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

The Food and Drug Administration has identified a Class I recall of Medtronic Aortic Root Cannulas due to a risk of ...